Glycotope’s target discovery unit acquisition will double Pentixapharm’s development pipeline, according to the company’s CEO. Image Credit: Vitalii Vodolazskyi / Shutterstock.

German radiopharmaceutical biotech Pentixapharm has acquired Germany-based Glycotope’s target discovery unit for an undisclosed sum to expand its oncology pipeline.

Pentixapharm plans to turn the preclinical antibodies against multiple cancer targets into radiopharmaceuticals. In addition to the preclinical assets, the company added Glycotope’s laboratories, cell banks, tumour target database, and equipment to its portfolio.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

“The acquisition will broaden Pentixapharm’s Intellectual Property portfolio beyond the one built around the CXCR4 receptor. This will immediately double the development pipeline and significantly expand the associated business and clinical development opportunities,” explained Pentixapharm CEO Hakim Bouterfa.

“Glycotope’s pipeline comprises several candidates that can be used immediately for proof-of-concept studies as next-generation radiopharmaceuticals. We look forward to maximising the synergy of Pentixapharm’s know-how and Glycotope’s target discovery for the benefit of patients in both diagnostics and therapeutic applications.”

Pentatixapharm’s clinical pipeline consists of PentixaTher, a Yttrium-90-based treatment for central nervous system lymphoma. The radiotherapy is being evaluated in an open-label Phase I/II dose-finding trial (NCT06132737). The company is also developing a companion diagnostic for PentixaTher, called PentixaFor. The diagnostic is being trialled in a Phase III trial (NCT06125028) for staging of marginal zone lymphoma, a subtype of non-Hodgkin B-cell lymphoma.

See Also:

The acquisition will also see around 40 of Glycotope’s staff, including executives, R&D specialists, and administrators, added to Pentixapharm’s employment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

While Pentixapharm is currently owned by Eckert & Ziegler (EZAG), a company specialising in providing isotope-related components for medical, scientific and industrial use, it plans to detach from EZAG and list on the Frankfurt Stock Exchange.

Radiopharmaceuticals have been an area of interest in the past few years, attracting significant investment and acquisitions. Eli Lilly has signed two high-profile deals for radiopharmaceuticals; a $140m partnership with Radionetics Oncology and a discovery collaboration agreement with Aktis Oncology potentially worth over $1.7bn.

Bristol Myers Squibb also jumped on the radiopharmaceuticals trend and paid $4.2bn to acquire RayzeBio. Novartis also shelled out $1.75bn and purchased US-based Mariana Oncology. AstraZeneca also started its radiopharmaceutical pipeline with a $2.4bn acquisition of Fusion Pharmaceuticals in March this year.